CBRE Clarion Global Real Estate Income Fund (IGR) to pay $0.05 on Feb 28, 2018; Last Week Cellectis S.A. (CLLS) Coverage

February 15, 2018 - By Adrian Mccoy

CBRE Clarion Global Real Estate Income Fund (NYSE:IGR) is expected to pay $0.05 on Feb 28, 2018. $0.60 is the ADY. (NYSE:IGR) shareholders before Feb 16, 2018 will receive the $0.05 dividend. CBRE Clarion Global Real Estate Income Fund’s current price of $7.29 translates into 0.69% yield. CBRE Clarion Global Real Estate Income Fund’s dividend has Feb 20, 2018 as record date. Feb 1, 2018 is the announcement. The stock decreased 0.55% or $0.04 during the last trading session, reaching $7.29. About 499,604 shares traded or 45.20% up from the average. CBRE Clarion Global Real Estate Income Fund (NYSE:IGR) has declined 3.62% since February 15, 2017 and is downtrending. It has underperformed by 20.32% the S&P500.

Among 7 analysts covering Cellectis (NASDAQ:CLLS), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Cellectis had 13 analyst reports since April 5, 2016 according to SRatingsIntel. The stock of Cellectis S.A. (NASDAQ:CLLS) earned “Buy” rating by Jefferies on Thursday, August 24. The firm earned “Buy” rating on Wednesday, September 6 by Nomura. Jefferies maintained the stock with “Buy” rating in Monday, September 25 report. SunTrust downgraded Cellectis S.A. (NASDAQ:CLLS) on Wednesday, September 6 to “Hold” rating. As per Friday, October 6, the company rating was maintained by SunTrust. The stock of Cellectis S.A. (NASDAQ:CLLS) has “Buy” rating given on Tuesday, April 5 by Ladenburg Thalmann. The rating was downgraded by Morgan Stanley to “Sell” on Monday, October 2. The stock has “Buy” rating by Oppenheimer on Friday, June 2. The firm earned “Buy” rating on Wednesday, August 16 by Oppenheimer. As per Tuesday, June 6, the company rating was maintained by Jefferies. See Cellectis S.A. (NASDAQ:CLLS) latest ratings:

27/10/2017 Broker: Jefferies Rating: Buy New Target: $47.0 Maintain
06/10/2017 Broker: SunTrust Rating: Hold New Target: $20.0 Maintain
02/10/2017 Broker: Morgan Stanley Rating: Sell Downgrade
25/09/2017 Broker: Jefferies Rating: Buy New Target: $47.0 Maintain
06/09/2017 Broker: SunTrust Rating: Hold New Target: $20.0 Downgrade
06/09/2017 Broker: Nomura Rating: Buy Old Target: $49 New Target: $43 Maintain
24/08/2017 Broker: Jefferies Rating: Buy New Target: $47.0 Maintain
16/08/2017 Broker: Oppenheimer Rating: Buy New Target: $40.0 Maintain

Investors sentiment increased to 1.19 in 2017 Q3. Its up 0.05, from 1.14 in 2017Q2. It is positive, as 8 investors sold CBRE Clarion Global Real Estate Income Fund shares while 18 reduced holdings. 8 funds opened positions while 23 raised stakes. 20.53 million shares or 0.50% more from 20.43 million shares in 2017Q2 were reported. Thrivent Financial For Lutherans stated it has 0% in CBRE Clarion Global Real Estate Income Fund (NYSE:IGR). Burney Com has invested 0.13% of its portfolio in CBRE Clarion Global Real Estate Income Fund (NYSE:IGR). Parametric Assocs Limited Liability Corporation holds 0% or 431,960 shares in its portfolio. Blackrock accumulated 300 shares. Nuveen Asset Mgmt Limited Liability reported 17,117 shares. Meridian Counsel reported 49,366 shares. Hl Fin Ltd Liability Co holds 116,588 shares or 0.02% of its portfolio. Limited Liability Com reported 16,913 shares. Ameriprise Financial Incorporated accumulated 0% or 241,502 shares. Stifel Corp holds 242,153 shares. Cornerstone Advsrs Inc, a Alabama-based fund reported 1.29 million shares. Commonwealth Equity Service owns 175,052 shares. Hanson Mcclain holds 882 shares. Sii Wi reported 16,452 shares. Citigroup accumulated 4,727 shares.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company has market cap of $1.10 billion. The firm operates through two divisions, Therapeutics and Plants. It currently has negative earnings. The Company’s lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia and CLL.

The stock increased 3.28% or $1.01 during the last trading session, reaching $31.79. About 113,291 shares traded. Cellectis S.A. (NASDAQ:CLLS) has declined 17.09% since February 15, 2017 and is downtrending. It has underperformed by 33.79% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: